Modern says people who received the Covid vaccine last year are almost TWICE more likely to get an advanced infection compared to people who recently received the vaccine.
- New data from Moderna found 88 advanced cases of COVID-19 of people fully vaccinated between December 2020 and March 2021
- Comparatively, there are 162 advanced cases among those vaccinated between July 2020 and December 2020 during clinical trials
- Modern says these data suggest that fully vaccinated people should receive booster vaccines six to eight months after their final dose.
- Early data showed that a third dose increased the levels of neutralizing antibodies increased up to 15 times after one month.
Modern Inc. says people who received the COVID-19 vaccine last year are almost twice as likely to get an advanced infection compared to those recently vaccinated.
Advanced cases occur when people contract the disease 14 days or more after receiving their final dose of the shot.
New data released Wednesday found 88 advanced cases of COVID-19 among vaccinated Americans from December 2020 to March 2021.
Comparatively, there were 162 cases, 1.8 times more, among those vaccinated between July 2020 and December 2020.
The Cambridge, Massachusetts-based company also reported 13 serious cases among the early vaccination group compared to six in the later group.
In addition, there were three Covid hospitalizations and two deaths in the vaccinated group last year compared to no hospitalizations or deaths in the vaccinated group in the winter of 2020 and spring of 2021.
Modern says the data provides evidence to give booster doses to fully vaccinated people.
Moderna’s new data found 88 advanced cases of COVID-19 among those fully vaccinated from December 2020 and March 2021 compared to 162 cases among those vaccinated between July 2020 and December 2020. Pictured: a vial of the COVID-19 vaccine from Moderna, on April 7th.
People who received their first dose last year were more likely to suffer serious progress, be hospitalized, or die compared to vaccinations from the winter of 2020 through the spring of 2021.
The data examined people who participated in Moderna’s Phase 3 COVE study last year and people who received the vaccine after receiving emergency use authorization from the Food and Drug Administration. (FDA) of the USA.
Of the 14,746 who received the vaccine between July 2020 and December 2020, there were 162 advanced Covid cases.
In comparison, there were 88 advanced cases among 11,431 who received the vaccine from December 2020 to March 2021.
Researchers say this means there is a reduced 36% protection against those who received their first dose 13 months ago compared to those who received their initial shot eight months ago.
For both groups, more cases were observed among younger adults.
Modern says these data suggest that fully vaccinated people should receive booster vaccines six to eight months after their final dose. In the photo: a health worker administers a shot of the Modern COVID-19 vaccine in New York City, January 2021
In the 2020 vaccination group, there were 136 advanced cases for young people aged 18 to 65 years and 26 cases were observed among the group aged 65 and over.
In the 2020-21 vaccination group, there were 68 advanced cases among the younger adult group and 20 cases among the elderly.
More severe cases of COVID-19 were observed in the early vaccination group with 13 cases compared with six cases in the later group.
Seven serious cases of progress were reported among young people aged 18 to 65 who were vaccinated last year compared with six in the group aged 65 and over.
Moderna says this represents a 46% reduction in protection against serious cases among those who received the vaccine about a year ago.
Among the most recently vaccinated group, four cases were in young adults and two in older adults.
And while the group that was shot last year had three advanced cases that resulted in hospitalizations and two deaths, none of those shot that year occurred.
“The increased risk of advanced infections in … study participants who were vaccinated last year compared to more recently illustrates the impact of decreased immunity and supports the need of a reinforcement to maintain high levels of protection, “Moderna CEO Stéphane Bancel said in a press release.
“We hope these findings will be helpful, as health authorities and regulators continue to evaluate strategies to end this pandemic.”
Moderna also shared data from her clinical trial on people who received reinforcement victims six to eight months after their second dose.
They found that neutralizing antibody levels increased up to 15 times after a month.
Levels, even among older adults, who typically produce much weaker immune responses, were even higher than those recorded immediately after the second dose.
